Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...

Leaders don’t fail from complexity overload. They fail from pretending it’s simple, then engineering systems that move ...

One way leads to a future in which AI-driven breakthroughs remain the exclusive domain of pharmaceutical giants with billion-dollar budgets. The other, to a landscape where breakthroughs regularly ...

Sundance: Telling three parallel stories at various points in time, Stanton's film spans 47,000 years in search of a single ...

Integrated Biosciences, a biotechnology company combining synthetic biology, chemistry, and AI to discover small-molecule therapeutics for age-related diseases, today announced the appointment of ...

Confusing efficiency with productivity is to mistake speed for direction, and execution for value. Hamilton Mann explains how to avoid the pitfalls in your AI transformation ...

Cellino, a regenerative medicine company developing autonomous manufacturing systems for personalized cells, today announced the expansion of co-founder Dr. Marinna Madrid's role to Chief Product and ...

Burnaby man builds monument to romantic collapse; mother contributes wedding dress.

Python.Org is the official source for documentation and beginner guides. Codecademy and Coursera offer interactive courses ...

Ricursive joins Recursive and Unconventional AI in raising massive funds at multi-billion valuations out of the gate.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...